Utah Medical Products Inc.

UTMD

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0000706698

A

strongest fifth of 369 graded peers in healthcare

rank 49 of 369; percentile 13.0; sampling error 2.5 points; lower is stronger

A B C D E


A, the bull



Scoreboard


Profitability	C	percentile 46.7
Solvency	A	percentile 0.9
Growth and financing	C	percentile 57.0
Reliability	0.87 AUC	filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year	Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets	total assets $122.5M
Standard universe	inside	revenue above $1M and assets above $10M
Warnings	none triggered; fortress balance sheet	not computable: distress
Inputs computable	12 of 14	
Graded from	filings received through Mar 27, 2026	219 days before the rescan; latest periodic filing 10-Q received Aug 12, 2026
Last close	$68.33	2026-10-30; market equity $217.6M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 27, 2026

Currency amounts throughout this report are in thousands except per-share amounts and where noted. Utah Medical Products, Inc. ("UTMD" or "the Company") is in the business of producing high quality cost-effective medical devices that are predominantly differentiated by safety and improved patient outcomes. Throughout this report, "UTMD" or "the Company" refers jointly to Utah Medical Products, Inc. and all of its corporate subsidiaries.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 46.7						
Gross profitability	18.0%	32.4%		66.8	366	2025-12-31
Return on invested capital	26.6%	9.3%		11.0	74	2025-12-31
Accruals ratio	(2.8%)	(6.6%)		72.3	803	2025-12-31
Gross margin stability, five years	2.0 pts	2.8 pts		36.5	242	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Solvency, sleeve percentile 0.9						
Twelve-month failure probability	not computable	0.08%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	47.39	(0.35)	0.4	748	2025-12-31	
Net debt to EBITDA	(6.99x)	1.82x	1.4	75	2025-12-31	
Interest coverage	not computable	(4.51x)				
interest expense must exceed $100,000						
Current ratio	37.62x	2.92x	1.0	829	2025-12-31	
Growth and financing, sleeve percentile 57.0						
Revenue growth, three-year compound	(9.7%)	10.1%	85.2	412	2025-12-31	
Free cash flow growth, three-year compound	(11.0%)	10.9%	86.3	96	2025-12-31	
Reinvestment rate	23.2%	37.1%	55.3	104	2025-12-31	
Asset growth, three years	(0.4%)	2.2%	52.2	696	2025-12-31	
Net share issuance, one year	(2.9%)	2.5%	6.0	631	2026-03-26	


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 85,531,000 USD; Altman Z is not used

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
44	Idexx Laboratories Inc. (IDXX)	11.7	A	
45	Natera, Inc. (NTRA)	12.0	A	fortress balance sheet
46	Procept BioRobotics Corp. (PRCT)	12.2	A	fortress balance sheet
47	PRO DEX Inc. (PDEX)	12.5	A	
48	Insulet Corp. (PODD)	12.8	A	
49	Utah Medical Products Inc. (UTMD)	13.0	A	fortress balance sheet
50	Ardelyx, Inc. (ARDX)	13.3	A	
51	Resmed Inc. (RMD)	13.6	A	fortress balance sheet
52	Gyre Therapeutics, Inc. (GYRE)	13.9	A	fortress balance sheet
53	Treace Medical Concepts, Inc. (TMCI)	14.1	A	
54	Janux Therapeutics, Inc. (JANX)	14.4	A	

What the price implies

at the 2026-10-30 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	29.4%	(2.2%)	69
Distance from 52-week high	(11.2%)	(28.7%)	74
EBIT to enterprise value	8.8%	(1.4%)	89
Free cash flow yield	6.6%	(1.0%)	87

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Book value to price	0.56	0.28	74
Sales to price	0.18	0.30	37
Composite equity issuance, five years	(23.5%)	20.5%	6
Relative strength against the sector, log excess return	0.09	(0.19)	69

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 7 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$87.5M
Operating cash flow, four quarters	$11.8M
Months of runway	not finite
Days since last periodic filing	81 (10-Q received Aug 12, 2026)
Median daily dollar volume, 63 sessions	$2.3M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$22.0M	2025-12-31	2026-03-27	10-K	26-000395
2	assets	us-gaap:Assets	$122.5M	2025-12-31	2026-03-27	10-K	26-000395
3	operating income	us-gaap:OperatingIncomeLoss	$11.4M	2025-12-31	2026-03-27	10-K	26-000395
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$14.1M	2025-12-31	2026-03-27	10-K	26-000395
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$2.8M	2025-12-31	2026-03-27	10-K	26-000395
6	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	$225,000	2025-12-31	2026-03-27	10-K	26-000395
7	book equity	us-gaap:StockholdersEquity	$119.3M	2025-12-31	2026-03-27	10-K	26-000395
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$85.8M	2025-12-31	2026-03-27	10-K	26-000395
9	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	$282,000	2024-12-31	2026-03-27	10-K	26-000395
10	book equity	us-gaap:StockholdersEquity	$117.4M	2024-12-31	2026-03-27	10-K	26-000395
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$83.0M	2024-12-31	2026-03-27	10-K	26-000395
12	net income	us-gaap:ProfitLoss	$11.3M	2025-12-31	2026-03-27	10-K	26-000395
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$14.7M	2025-12-31	2026-03-27	10-K	26-000395
14	assets	us-gaap:Assets	$122.5M	2024-12-31	2026-03-27	10-K	26-000395
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$38.5M	2025-12-31	2026-03-27	10-K	26-000395
16	gross profit	us-gaap:GrossProfit	$24.1M	2024-12-31	2026-03-27	10-K	26-000395
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$40.9M	2024-12-31	2026-03-27	10-K	26-000395
18	gross profit	us-gaap:GrossProfit	$30.0M	2023-12-31	2026-03-27	10-K	26-000395
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$50.2M	2023-12-31	2026-03-27	10-K	26-000395
20	gross profit	us-gaap:GrossProfit	$32.2M	2022-12-31	2025-03-26	10-K	25-000308
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$52.3M	2022-12-31	2025-03-26	10-K	25-000308
22	gross profit	us-gaap:GrossProfit	$30.9M	2021-12-31	2024-03-26	10-K	24-000009
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$49.1M	2021-12-31	2024-03-26	10-K	24-000009
24	current assets	us-gaap:AssetsCurrent	$97.7M	2025-12-31	2026-03-27	10-K	26-000395
25	current liabilities	us-gaap:LiabilitiesCurrent	$2.6M	2025-12-31	2026-03-27	10-K	26-000395
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$128.7M	2025-12-31	2026-03-27	10-K	26-000395

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

27	liabilities	us-gaap:Liabilities	$3.3M	2025-12-31	2026-03-27	10-K	26-000395
28	depreciation amortization	us-gaap:Depreciation	$826,000	2025-12-31	2026-03-27	10-K	26-000395
29	operating income	us-gaap:OperatingIncomeLoss	$15.7M	2015-12-31	2018-03-06	10-K	18-000127
30	interest expense	us-gaap:InterestExpense	$65,000	2015-12-31	2018-03-06	10-K	18-000127
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$371,000	2025-12-31	2026-03-27	10-K	26-000395
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$14.8M	2024-12-31	2026-03-27	10-K	26-000395
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$230,000	2024-12-31	2026-03-27	10-K	26-000395
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$22.3M	2023-12-31	2026-03-27	10-K	26-000395
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$639,000	2023-12-31	2026-03-27	10-K	26-000395
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$21.1M	2022-12-31	2025-03-26	10-K	25-000308
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$809,000	2022-12-31	2025-03-26	10-K	25-000308
38	current assets	us-gaap:AssetsCurrent	$96.3M	2024-12-31	2026-03-27	10-K	26-000395
39	current liabilities	us-gaap:LiabilitiesCurrent	$3.8M	2024-12-31	2026-03-27	10-K	26-000395
40	assets	us-gaap:Assets	$135.5M	2023-12-31	2025-03-26	10-K	25-000308
41	assets	us-gaap:Assets	$123.9M	2022-12-31	2024-03-26	10-K	24-000009
42	shares outstanding	dei:EntityCommonStockSharesOutstanding	3,185,025	2026-03-26	2026-03-27	10-K	26-000395
43	shares outstanding	dei:EntityCommonStockSharesOutstanding	3,281,816	2025-03-25	2025-03-26	10-K	25-000308

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.